H&T Presspart and Hovione Technology Enter Dry Powder Inhalation Partnership

H&T Presspart's PowdAir Plus Dry Powder Inhaler

H&T Presspart, the world’s leading manufacturer of components for metered dose inhalers (MDIs), today announced a collaborative partnership with Hovione Technology, supporting a strategic plan to expand its portfolio of novel drug delivery systems in respiratory care.

"We are delighted with the collaboration with H&T Presspart. With our expertise in DPI invention, design and development and Presspart’s mastery of large scale industrialization and global distribution, we are very confident about success,” said Peter Villax, CEO of Hovione Technology, a company founded by the shareholders of Hovione, a 58-year old manufacturer of Active Pharmaceutical Ingredients (APIs).

Pharmaceutical companies that work with H&T Presspart on this device can also access Hovione’s expertise in API formulation and manufacturing alongside H&T Presspart’s state- of-the-art manufacturing capabilities and experience in industrialising products for pharmaceutical companies.

PowdAir Plus has been developed in response to the recognised need to offer patients in developing markets more choice of DPIs. Most DPIs have been designed for developed markets and incorporate multiple components and complex mechanics.

PowdAir Plus is a complete unit with has no metal or separate parts, and was designed to be robust to withstand the mechanical stresses of frequent use. Throughout the design process, functionality was of utmost importance and PowdAir Plus delivers an effective dose of medication with each capsule in line with expected market performance. It is compatible with all capsule types (i.e. gelatine and HPMC) in size 3, so can be used with any dry powder medicines.

A particularly novel design feature is the way in which the device opens the capsule once the tray is closed, removing the need for patients to actively pierce the capsule and reducing the number of operational steps. By enhancing ease of use, the design also removes the risk of errors that may affect a treatment’s efficacy.

“As demand in developing markets is increasing, pharmaceutical companies are looking for devices that deliver reliable performance and meet high patient expectations for ease of use, but at a reduced cost,” said Peter Schmelzer.